Answers are grounded in this paper and cite their sources.
Investigates ephrin-B2's role in blood-spinal cord barrier integrity post-spinal cord injury, indicating a potential therapeutic target.
Traumatic Spinal Cord Injury (SCI) disrupts the Blood-Spinal Cord Barrier (BSCB), amplifying injury processes. Targeted therapies require deeper insight into underlying mechanisms. Endothelial Ephrin-B2, a guidance molecule regulating cell adhesion and repulsion, might influence the BSCB, but its role after SCI remains unknown. This study investigates Ephrin-B2 in endothelial cells (ECs) and its influence on BSCB integrity in a mouse SCI model up to 28 days. Transgenic mice with Tamoxifen-inducible EC-specific Ephrin-B2 knockdown (efnb2iΔEC, n = 79) and Cre-negative littermates (efnb2lox/lox, n = 71) received serial Tamoxifen-injections. Animals underwent thoracic clip-compression injury (Th6/7, 60s, 5 g, n = 128) or Sham injury (laminectomy, n = 22). At postoperative days 1, 3, 7, 14 and 28 in vivo analysis included neurological assessment (Basso Mouse Scale, Tally Subscore, CatWalkTM automated gait analysis) and 7 T MRI (T2 Turbo Rare). Ex vivo analysis included Evans Blue assay ( n = 5 per group/timepoint), vessel perfusion, and immunohistochemistry ( n = 4 per group/timepoint) examining vessel density (CD31, FITC-Lectin), pericyte coverage (CD31, Desmin, PDGFR-beta), and junction proteins (Claudin-5, VE-Cadherin). efnb2iΔEC mice showed increased BSCB disruption during the acute phase (1d: p = 0.0117; 3d: p = 0.0153) accompanied by a trend for increased edema on day 1 after SCI ( p = 0.0712). Vascular and junctional markers revealed posttraumatic impairment with regeneration after day 7, without significant inter-group differences ( p > 0.05). Neurological recovery however was not influenced by EC-specific Ephrin-B2 knockdown (p > 0.05). Endothelial Ephrin-B2 is crucial for BSCB resilience after SCI. Its EC- specific knockdown aggravates barrier disruption and influences edema volume, suggesting Ephrin-B2 as a potential therapeutic target for acute SCI. • Ephrin-B2 is upregulated after SCI, but its role remains largely unexplored. • Endothelial Ephrin-B2 knockdown aggravates BSCB breakdown and increases edema. • Endothelial Ephrin-B2 may be a therapeutic target to stabilize the BSCB after SCI.
No takes yet. Share an insight, caveat, or question.
Kersting et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: